A novel drug-loaded multilayered cardiac patch demonstrates excellent in vitro cytocompatibility and antifibrotic activity, suggesting potential as a platform for ischemic tissue regeneration.
Supports multi-layered cardiac patch development; leaves open clinical translation pending in vivo validation.
biological assessments confirmed excellent cytocompatibility across all layers, supporting an H9c2 cardiomyoblast viability of roughly 90% after 72 hours. Human iPSC-CMs cultured on the patch maintained spontaneous and synchronous beating activity. Moreover, the patch loaded with PIR exhibited significant antifibrotic activity, confirming that the released drug remained biologically active. Ultimately, this multi-layered design provides a promising and functionally active platform for counteracting pathological remodeling and restoring myocardial tissue.
No takes yet. Share an insight, caveat, or question.
Rossino et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: